Gentian Diagnostics AS (OSL:GENT) Total Equity: kr185.2 Mil (As of Mar. 2026)


OSL:GENT Gentian Diagnostics AS OSL:GENT
72 GF Score
Price kr37.00
GF Value kr61.81
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Gentian Diagnostics AS Total Equity?

Gentian Diagnostics AS OSL:GENT -4.88% 72 Total Equity is kr185.2 Mil as of Mar. 2026. GuruFocus rates OSL:GENT with a GF Score™ of 72/100 and a GF Value™ of kr61.81 (Possible Value Trap). The stock has 1 warning sign investors should review.

Gentian Diagnostics AS's total equity for the quarter that ended in Mar. 2026 was kr185.2 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Gentian Diagnostics AS Total Equity Historical Data

* Premium members only.

The historical data trend for Gentian Diagnostics AS's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS Total Equity Chart

Gentian Diagnostics AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 174.77 154.17 146.64 194.05 204.96

Gentian Diagnostics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 203.49 197.46 202.02 204.96 185.21
OSL:GENT
72GF Score
Gentian Diagnostics AS OSL:GENT
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gentian Diagnostics AS Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Gentian Diagnostics AS's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=258.539-53.582
=205.0

Gentian Diagnostics AS's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=235.497-50.289
=185.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr185.2 Mil mean?
Gentian Diagnostics AS (OSL:GENT) has a Total Equity of kr185.2 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Gentian Diagnostics AS and its competitors.
Is Gentian Diagnostics AS's Total Equity too high?
Gentian Diagnostics AS's current Total Equity is kr185.2 Mil. Overall, Gentian Diagnostics AS has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Total Equity compare to ABT and SYK?
Gentian Diagnostics AS's Total Equity of kr185.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current Total Equity is kr185.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Possible Value Trap. The stock's GF Value™ is kr61.81, compared to a current price of kr37.00 — trading 40.1% below its estimated fair value. The current Total Equity is kr185.2 Mil. Gentian Diagnostics AS's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current Total Equity is kr185.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr37.00 is trading 40.1% below its estimated GF Value™ of kr61.81. GuruFocus considers Gentian Diagnostics AS to be Possible Value Trap.

Key valuation signals for OSL:GENT:

  • Total Equity: kr185.2 Mil
  • GF Value™: kr61.81 vs. price of kr37.00 (40.1% below fair value)
  • GF Score™: 72/100 with 1 warning sign

No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gentian Diagnostics AS Business Description

Other Exchanges GENTOo:Sweden6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
72GF Score

Get the complete analysis for OSL:GENT

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr37.00
Price
kr61.81
GF Value